SCHEMBL12833232

SCHEMBL12833232

O=C(c1cccnc1Cl)N1CCN(Cc2ccccc2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.58
POLB P06746 1/20 0.57
ALDH1A1 P00352 4/20 0.57
KDM4E B2RXH2 2/20 0.57
SMN1; SMN2 Q16637 3/20 0.56
TSHR P16473 2/20 0.56
MEN1 O00255 1/20 0.56
MAPK1 P28482 1/20 0.56
KMT2A Q03164 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
CHRM2 P08172 1/20 0.55
PRKAB2 O43741 1/20 0.55
PRKAG1 P54619 1/20 0.55
PRKAA2 P54646 1/20 0.55
PRKAA1 Q13131 1/20 0.55
PRKAG3 Q9UGI9 1/20 0.55
PRKAG2 Q9UGJ0 1/20 0.55
PRKAB1 Q9Y478 1/20 0.55
MAPK14 Q16539 2/20 0.55
HTT P42858 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14459990 0.86 LMNA (0.64) LMNAALDH1A1KDM4ESMN1; SMN2TSHR
SCHEMBL7130439 0.84 LMNA (0.72) LMNAALDH1A1KDM4ESMN1; SMN2TSHR
SCHEMBL1976542 0.83 POLB (0.65) LMNAPOLBALDH1A1KDM4ESMN1; SMN2
SCHEMBL21011063 0.83 LMNA (0.54) LMNAALDH1A1KDM4ESMN1; SMN2TSHR
SCHEMBL14459989 0.82 POLB (0.60) LMNAPOLBALDH1A1KDM4ESMN1; SMN2
SCHEMBL13116745 0.81 ALDH1A1 (0.68) LMNAPOLBALDH1A1KDM4ESMN1; SMN2
SCHEMBL15853630 0.80 RORC (0.62) POLB
SCHEMBL14840498 0.80 CYP46A1 (0.69) POLBCYP2C19
Piberaline SCHEMBL49391 0.80 L3MBTL1 (0.71) LMNAALDH1A1KDM4ESMN1; SMN2TSHR
SCHEMBL2701589 0.79 CYP46A1 (0.53) LMNAPOLBALDH1A1SMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9481649-B2 Synthesis of a neurostimulative piperazine NEURALSTEM, INC. (US) 2016-11-01 US disclosed
US-9481649-B2 Synthesis of a neurostimulative piperazine NEURALSTEM, INC. (US) 2016-11-01 US disclosed
US-20160090358-A1 SYNTHESIS OF A NEUROSTIMULATIVE PIPERAZINE NEURALSTEM, INC. (US) 2016-03-31 US disclosed
US-20160090358-A1 SYNTHESIS OF A NEUROSTIMULATIVE PIPERAZINE NEURALSTEM, INC. (US) 2016-03-31 US disclosed
US-9278933-B2 Synthesis of a neurostimulative piperazine NEURALSTEM, INC. (US) 2016-03-08 US disclosed
US-9278933-B2 Synthesis of a neurostimulative piperazine NEURALSTEM, INC. (US) 2016-03-08 US disclosed
EP-2470182-B1 SYNTHESIS OF A NEUROSTIMULATIVE PIPERAZINE NEURALSTEM INC (US) 2014-06-04 EP disclosed
US-20130072497-A1 N- SUBSTITUTED PIPERAZINES DOW AGROSCIENCES LLC (US) 2013-03-21 US disclosed
US-20130072497-A1 N- SUBSTITUTED PIPERAZINES DOW AGROSCIENCES LLC (US) 2013-03-21 US disclosed
US-20130005974-A1 SYNTHESIS OF A NEUROSTIMULATIVE PIPERAZINE NEURALSTEM, INC. (US) 2013-01-03 US disclosed
US-20130005974-A1 SYNTHESIS OF A NEUROSTIMULATIVE PIPERAZINE NEURALSTEM, INC. (US) 2013-01-03 US disclosed
US-8338430-B2 N-substituted piperazines DOW AGROSCIENCES, LLC. (US) 2012-12-25 US disclosed
US-8338430-B2 N-substituted piperazines DOW AGROSCIENCES, LLC. (US) 2012-12-25 US disclosed
WO-2011028548-A1 SYNTHESIS OF A NEUROSTIMULATIVE PIPERAZINE NEURALSTEM, INC. (US) 2011-03-10 WO disclosed
US-20100234391-A1 N-SUBSTITUTED PIPERAZINES DOW AGROSCIENCES LLC (US) 2010-09-16 US disclosed
US-20100234391-A1 N-SUBSTITUTED PIPERAZINES DOW AGROSCIENCES LLC (US) 2010-09-16 US disclosed
US-7754724-B2 N-substituted piperazines DOW AGROSCIENCES LLC (US) 2010-07-13 US disclosed
US-7754724-B2 N-substituted piperazines DOW AGROSCIENCES LLC (US) 2010-07-13 US disclosed
US-20070004750-A1 N-substituted piperazines CORTEVA AGRISCIENCE LLC 2007-01-04 US disclosed
US-20070004750-A1 N-substituted piperazines CORTEVA AGRISCIENCE LLC 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004750-A1 N-substituted piperazines PRXL2A, CNPY2, CYP4X1 LMNA 3135/4885POLB 4163/4885ALDH1A1 641/4885
US-20100234391-A1 N-SUBSTITUTED PIPERAZINES PRXL2A, CNPY2, CYP4X1 LMNA 3135/4885POLB 4163/4885ALDH1A1 641/4885
US-20130005974-A1 SYNTHESIS OF A NEUROSTIMULATIVE PIPERAZINE GAP43, AANAT, NNMT LMNA 2898/4885POLB 2110/4885ALDH1A1 1359/4885
US-20130072497-A1 N- SUBSTITUTED PIPERAZINES PRXL2A, CNPY2, CYP4X1 LMNA 3135/4885POLB 4163/4885ALDH1A1 641/4885
US-20160090358-A1 SYNTHESIS OF A NEUROSTIMULATIVE PIPERAZINE GAP43, AANAT, NNMT LMNA 2898/4885POLB 2110/4885ALDH1A1 1359/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.